Related Experiment Video

Updated: Sep 23, 2025

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.4K

TFPI inhibits breast cancer progression by suppressing ERK/p38 MAPK signaling pathway

Mengying Xing1, Ying Yang1, Jiaxue Huang1

  • 1Department of Medical Genetics, School of Basic Medical Sciences, Nanjing Medical University, 101 Longmian Avenue, Nanjing, 211166, Jiangsu, People's Republic of China.

Genes & Genomics
|May 14, 2022
PubMed
Abstract

Insights

Tissue factor pathway inhibitor-1 (TFPI) is downregulated in breast cancer, correlating with worse survival. TFPI inhibits cancer cell proliferation, migration, and invasion by affecting the ERK/p38 MAPK pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tissue factor pathway inhibitor-1 (TFPI) is a key regulator of coagulation.
  • Emerging evidence suggests TFPI possesses antitumor properties.
  • TFPI expression is often reduced in various cancer types.

Purpose of the Study:

  • To investigate the role of TFPI in breast cancer.
  • To elucidate the molecular mechanisms underlying TFPI's function in breast cancer.
  • To assess TFPI as a potential prognostic biomarker and therapeutic target.

Main Methods:

  • Bioinformatic analysis using UALCAN and Kaplan-Meier plotter.
  • Immunohistochemistry and Western blot for TFPI expression.
  • Cell proliferation, migration, and invasion assays (CCK-8, colony formation, transwell).
  • Methylation-specific PCR to assess promoter methylation.

Main Results:

  • TFPI expression is significantly decreased in breast cancer tissues and cells.
  • Low TFPI levels correlate with poorer overall survival.
  • TFPI overexpression inhibits, while knockdown promotes, breast cancer cell proliferation, migration, and invasion.
  • TFPI acts by inhibiting the ERK/p38 MAPK signaling pathway.
  • DNA hypermethylation of the TFPI promoter contributes to its downregulation.

Conclusions:

  • TFPI suppresses breast cancer progression by inhibiting the ERK/p38 MAPK pathway.
  • TFPI demonstrates potential as a prognostic biomarker for breast cancer.
  • TFPI represents a promising therapeutic target for breast cancer treatment.
Keywords:
Breast cancerDNA methylationMAPK signaling pathwayTFPI

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.3K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.3K